文献速递间质性肺疾病

肺纤维化利益相关者峰会:NHLBI、三湖基金会与肺纤维化基金会联合研讨会报告

Pulmonary Fibrosis Stakeholder Summit: A Joint NHLBI, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop Report.
PubMed 文献 · Am J Respir Crit Care Med · 2024-01-01

尽管在肺纤维化机制、危险因素和生物标志物方面有进展,且已有药物延缓特发性肺纤维化和进展性肺纤维化的肺功能下降,该病仍有高发病率和高死亡率。

要点

  • 肺纤维化仍是高发病率和高死亡率的疾病,需持续推动研究和合作。
  • 已获批药物可延缓特发性肺纤维化和进展性肺纤维化的肺功能下降。
  • 研讨会聚焦新研究模型、早期诊断和临床试验设计三个方向的研究机会。

核心结论

  • 肺纤维化领域虽在机制、危险因素、生物标志物和药物方面取得进展,但疾病负担仍重,需催化持续进步和合作。
  • 研讨会列举了推进肺纤维化发病机制、治疗和结局理解的研究机会。

研究设计与样本

  • 研讨会分为三个主题:新模型与研究工具、早期疾病风险因素与诊断改进、临床试验设计创新。

主要发现

  • 已有两种药物获批延缓特发性肺纤维化的肺功能下降,一种药物获批延缓进展性肺纤维化的肺功能下降。
  • 研讨会总结了各主题的报告和讨论内容,并列举了研究机会。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite progress in elucidation of disease mechanisms, identification of risk factors, biomarker discovery, and the approval of two medications to slow lung function decline in idiopathic pulmonary fibrosis and one medication to slow lung function decline in progressive pulmonary fibrosis, pulmonary fibrosis remains a disease with a high morbidity and mortality. In recognition of the need to catalyze ongoing advances and collaboration in the field of pulmonary fibrosis, the NHLBI, the Three Lakes Foundation, and the Pulmonary Fibrosis Foundation hosted the Pulmonary Fibrosis Stakeholder Summit on November 8-9, 2022. This workshop was held virtually and was organized into three topic areas: 1) novel models and research tools to better study pulmonary fibrosis and uncover new therapies, 2) early disease risk factors and methods to improve diagnosis, and 3) innovative approaches toward clinical trial design for pulmonary fibrosis. In this workshop report, we summarize the content of the presentations and discussions, enumerating research opportunities for advancing our understanding of the pathogenesis, treatment, and outcomes of pulmonary fibrosis.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Montesi SB, Gomez CR, Beers M, et al. Pulmonary Fibrosis Stakeholder Summit: A Joint NHLBI, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop Report. Am J Respir Crit Care Med. 2024. PMID: 38113442. doi:10.1164/rccm.202307-1154WS

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。